MatthewPGoetzMD

Breast Cancer

Professor of Oncology and Professor of Pharmacology; Director, Mayo Breast Cancer Specialized Program of Research Excellence; Co-Leader, Women's Cancer Program, Mayo Clinic Cancer Center; Chair, Mayo Breast Research Group

Join to view full profile

Dr. Goetz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Goetz's full profile

Already have an account?

Office
200 1st Street SW
Rochester, MN 55905
Is this information wrong?

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1999 - 2003
University of Michigan Health SystemResidency, Internal Medicine, 1996 - 1999
University of Michigan Health SystemInternship, Internal Medicine, 1996 - 1997
University of North Dakota School of Medicine and Health SciencesClass of 1996

Certifications & Licensure

MN State Medical License 1999 - 2024
MI State Medical License 1998 - 2002
American Board of Internal Medicine Medical Oncology

Clinical Trials

Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary Start of enrollment: 2004 Feb 01
Completed
Phase 2
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors Start of enrollment: 2003 Nov 01
Completed
Phase 1
Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 2
Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer
Withdrawn
Phase 2
Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2006 Feb 01
Completed
Phase 2
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery Start of enrollment: 2006 Jul 01
Completed
Phase 1
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases Start of enrollment: 2003 Nov 01
Completed
Not Applicable
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline Start of enrollment: 2011 Mar 16
Active, not recruiting
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer Start of enrollment: 2009 May 01
Terminated
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary Start of enrollment: 2009 Sep 01
Completed
Phase 2
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer Start of enrollment: 2011 Mar 25
Active, not recruiting
Phase 1
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2011 May 02
Active, not recruiting
Phase 1
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Start of enrollment: 2013 Apr 10
Active, not recruiting
Phase 2
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Breast Cancer Genome Guided Therapy Study (BEAUTY) Start of enrollment: 2013 Feb 01
Active, not recruiting
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2019 Aug 28
Enrolling by invitation
Phase 2
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer Start of enrollment: 2020 Jan 10
Recruiting
Phase 2
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Start of enrollment: 2021 Jan 13
Recruiting
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Start of enrollment: 2020 Jun 08
Active, not recruiting
Phase 3
Roles: Contact
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31
Recruiting
Phase 3
Roles: Contact
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis Start of enrollment: 2024 Jul 31
Not yet recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Roberto A Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, Sherene Loi, Vincent de Jong, Jodi M Carter, Torsten O Nielsen, Samuel Leung, Nazia Riaz, Stephen Chia, Gérôm...> ;JAMA. 2024 Apr 2
Revisiting Combined Modality Therapy in Older Patients With Luminal Breast Cancer Through the Patient Lens.
Cynthia Chauhan, Robert W Mutter, Matthew P Goetz, Jean L Wright> ;Journal of Clinical Oncology. 2024 Apr 2
2 citations
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer.
Alkhatib, H., Conage-Pough, J., Roy Chowdhury, S., Shian, D., Zaid, D., Rubinstein, A., Sonnenblick, A., Peretz-Yablonsky, T., Granit, A., Carmon, E., Kohale, I., Wang...> ;Molecular Cancer. 2024 Jan 16
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer.
Jayaraman, S., Wu, X., Kalari, K., Tang, X., Kuffel, M., Bruinsma, E., Jalali, S., Peterson, K., Correia, C., Kudgus, R., Kaufmann, S., Renuse, S., Ingle, J., Reid, J....> ;NPJ Breast Cancer. 2023 Dec 19
Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer.
Dan Moldoveanu, Tanya L Hoskin, Courtney N Day, Amy K Schulze, Matthew P Goetz, Judy C Boughey> ;Breast Cancer Research and Treatment. 2024 Feb 1
ASO Visual Abstract: Clinical Behavior, Management, and Treatment Response of Estrogen Receptor-Low (1-10%) Breast Cancer.
Dan Moldoveanu, Tanya L Hoskin, Courtney N Day, Amy K Schulze, Matthew P Goetz, Judy C Boughey> ;Annals of Surgical Oncology. 2023 Oct 1
ASO Author Reflections: Low Estrogen Receptor (ER) Expression Breast Cancer Behaves More like ER Negative Disease and Influences Management.
Dan Moldoveanu, Matthew P Goetz, Judy C Boughey> ;Annals of Surgical Oncology. 2023 Oct 1
2 citations
Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1-10%) Breast Cancer.
Dan Moldoveanu, Tanya L Hoskin, Courtney N Day, Amy K Schulze, Matthew P Goetz, Judy C Boughey> ;Annals of Surgical Oncology. 2023 Oct 1
Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast.
Joshi, U., Budhathoki, P., Gaire, S., Yadav, S., Shah, A., Adhikari, A., Choong, G., Couzi, R., Giridhar, K., Leon-Ferre, R., Boughey, J., Hieken, T., Mutter, R., Rudd...> ;Breast Cancer Research and Treatment. 2023 Jul 1
6 citations
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
Ciara Catherine O'Sullivan, Robert Clarke, Matthew Philip Goetz, John Robertson> ;JAMA Oncology. 2023 Sep 1
1 citations
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
Gary N Schwartz, Peter A Kaufman, Karthik V Giridhar, Jonathan D Marotti, Mary D Chamberlin, Bradley A Arrick, Grace Makari-Judson, Matthew P Goetz, Shannon M Soucy, F...> ;Clinical Cancer Research. 2023 Aug 1
22 citations
Advances in systemic therapies for triple negative breast cancer.
Roberto A Leon-Ferre, Matthew P Goetz> ;BMJ. 2023 May 30
1 citations
Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors.
Xiaojia Tang, Kevin J Thompson, Krishna R Kalari, Jason P Sinnwell, Vera J Suman, Peter T Vedell, Sarah A McLaughlin, Donald W Northfelt, Alvaro Moreno Aspitia, Richar...> ;Breast Cancer Research. 2023 May 24
6 citations
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.
Jodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, Yaohua Ma, Xue Wang, David Zahrieh, David W Hillman, Kathleen S Tenner, Jennifer M Kachergus, Heather Ann Brauer, ...> ;Nature Communications. 2023 Apr 18
1 citations
Development and validation of a liquid chromatography-mass spectrometry assay for quantification of Z- and E- isomers of endoxifen and its metabolites in plasma from w...
Sarah A Buhrow, Emily J Koubek, Matthew P Goetz, Matthew M Ames, Joel M Reid> ;Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2023 Apr 15
8 citations
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
Tufia C Haddad, Vera J Suman, Antonino B D'Assoro, Jodi M Carter, Karthik V Giridhar, Brendan P McMenomy, Katelyn Santo, Erica L Mayer, Meghan S Karuturi, Aki Morikawa...> ;JAMA Oncology. 2023 Jun 1
1 citations
Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamo...
Emily J Koubek, Sarah A Buhrow, Stephanie L Safgren, Lee Jia, Matthew P Goetz, Matthew M Ames, Joel M Reid> ;Drug Metabolism and Disposition. 2023 Feb 1
1 citations
PDJ amplicon in triple negative breast cancer.
Alexander S Roesler, Smriti Malasi, Lori Koslosky, Peter Hartmayer, Tammey J Naab, Jodi M Carter, David Zahrieh, David Hillman, Roberto A Leon-Ferre, Fergus J Couch, M...> ;Scientific Reports. 2023 Jan 12
96 citations
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned int...
Stephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun-Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, Irfan C...> ;The Lancet. Oncology. 2023 Jan 1
2 citations
Disruption of estrogen receptor beta's DNA binding domain impairs its tumor suppressive effects in triple negative breast cancer.
Kirsten G M Aspros, Michael J Emch, Xiyin Wang, Malayannan Subramaniam, Megan L Hinkle, Esther P B Rodman, Matthew P Goetz, John R Hawse> ;Frontiers in Medicine. 2023 Jan 1
2 citations
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-ris...
Shani Paluch-Shimon, Patrick Neven, Jens Huober, Irfan Cicin, Matthew P Goetz, Chikako Shimizu, Chiun-Sheng Huang, Hans Joachim Lueck, Jane Beith, Eriko Tokunaga, Jess...> ;Therapeutic Advances in Medical Oncology. 2023 Jan 1
6 citations
Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancer.
Marshall D Behrens, Robert J Stiles, Gennett M Pike, Laura A Sikkink, Yongxian Zhuang, Jia Yu, Liewei Wang, Judy C Boughey, Matthew P Goetz, Mark J Federspiel> ;Molecular Therapy Oncolytics. 2022 Dec 15
25 citations
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
Olivia Pagani, Barbara A Walley, Gini F Fleming, Marco Colleoni, István Láng, Henry L Gomez, Carlo Tondini, Harold J Burstein, Matthew P Goetz, Eva M Ciruelos, Vered S...> ;Journal of Clinical Oncology. 2023 Mar 1
2 citations
Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer.
Lixuan Wei, Huanyao Gao, Jia Yu, Huan Zhang, Thanh Thanh L Nguyen, Yayun Gu, Marie R Passow, Jodi M Carter, Bo Qin, Judy C Boughey, Matthew P Goetz, Richard M Weinshil...> ;Cancer Research. 2023 Feb 3
7 citations
Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with animmunostimulatory bacterial transgene.
Kimberly B Viker, Michael B Steele, Ianko D Iankov, Susanna C Concilio, Arun Ammayappan, Brad Bolon, Nathan J Jenks, Matthew P Goetz, Eleni Panagioti, Mark J Federspie...> ;Molecular Therapy. Methods & Clinical Development. 2022 Sep 8
Join now to see all

Journal Articles

ERβ-Mediated Induction of Cystatins Results in Suppression of TGFβ Signaling and Inhibition of Triple-Negative Breast Cancer Metastasis
Matthew P Goetz, James N Ingle, Proceedings of the National Academy of Sciences
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Matthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine

Lectures

ER+ Metastatic Breast Cancer: Beyond CDK Inhibitors
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Atossa to Present a Trial in Progress Poster on Its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 9th, 2023
OS Advances Gather Steam in Breast CancerNovember 13th, 2022
Mayo Clinic Scientists Awarded $12.1 Million NCI Grant for Breast Most Cancers AnalysisOctober 20th, 2022
Join now to see all